ALSO NOTED: HGS pockets milestone money; CollaGenex files NDA; Large Scale Biology wins orphan drug status; and much more...

> Human Genome Sciences of Rockville, Maryland, has picked up $7 million in milestones from its partner, GlaxoSmithKline, which is advancing a late-stage diabetes therapy. Release

> CollaGenex has filed an NDA for Oracea, a treatment for rosacea. Story

> Large Scale Biology has won orphan drug status for its recombinant human Lysosomal Acid Lipase. Release

> Auxilium Pharmaceuticals of Malvern, Pennsylvania, has produced top-line findings from the Phase II trial for its androgen replacement product candidate. Release

And Finally… Researchers say obesity can be just as dangerous to your wealth as it is to your health. Story

Suggested Articles

Rachel Humphrey, M.D., who joined CytomX as chief medical officer after heading immuno-oncology at AstraZeneca and Eli Lilly, has made her exit.

Scientists have discovered a scorpion toxin could inspire treatments to block the inflammation that triggers chronic pain.

The phase 2 success keeps Hal Barron’s group on track to file for approval in multiple myeloma by the end of the year.